{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:36:03Z","timestamp":1707525363434},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,27]]},"DOI":"10.7759\/cureus.47778","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T08:21:58Z","timestamp":1698394918000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravenous Iron Technique Evaluation in Chronic Heart Failure With Iron Deficiency Anemia"],"prefix":"10.7759","author":[{"given":"Rohit","family":"Gosavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin B","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijeet","family":"Nashte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000052622.51963.fc","article-title":"Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure","volume":"107","author":"Ezekowitz JA","year":"2003","unstructured":"Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003, 107:223-5. 10.1161\/01.cir.0000052622.51963.fc","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray JJ","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, et al.. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012, 33:1787-847. 10.1093\/eurheartj\/ehs104","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy CW","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017, 136:e137-61. 10.1161\/CIR.0000000000000509","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.044","article-title":"Anemia and chronic heart failure: implications and treatment options","volume":"52","author":"Anand IS","year":"2008","unstructured":"Anand IS. Anemia and chronic heart failure: implications and treatment options. J Am Coll Cardiol. 2008, 52:501-11. 10.1016\/j.jacc.2008.04.044","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.02.013","article-title":"Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials","volume":"161","author":"Kotecha D","year":"2011","unstructured":"Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011, 161:822-31.e2. 10.1016\/j.ahj.2011.02.013","journal-title":"Am Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2006.05.006","article-title":"The interaction between heart failure and other heart diseases, renal failure, and anemia","volume":"26","author":"Silverberg DS","year":"2006","unstructured":"Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol. 2006, 26:296-306. 10.1016\/j.semnephrol.2006.05.006","journal-title":"Semin Nephrol"},{"key":"ref7","unstructured":"World Health Organization. The prevalence of anaemia in women : a tabulation of available information, 2nd ed. (1992). Accessed: August 10, 2023: https:\/\/apps.who.int\/iris\/handle\/10665\/58994."},{"key":"ref8","article-title":"Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"McMurray JJ","year":"2012","unstructured":"McMurray JJ, Parfrey PS, Adamson JW, et al.. Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012, 2:279-335.","journal-title":"Kidney Int Suppl"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-008-9089-7","article-title":"The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes","volume":"13","author":"Tang YD","year":"2008","unstructured":"Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008, 13:387-92. 10.1007\/s10741-008-9089-7","journal-title":"Heart Fail Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.582577","article-title":"Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program","volume":"113","author":"O'Meara E","year":"2006","unstructured":"O'Meara E, Clayton T, McEntegart MB, et al.. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006, 113:986-94. 10.1161\/CIRCULATIONAHA.105.582577","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.094","article-title":"Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure","volume":"51","author":"Tang WH","year":"2008","unstructured":"Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008, 51:569-76. 10.1016\/j.jacc.2007.07.094","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-009-6203-6","article-title":"Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis","volume":"23","author":"Tehrani F","year":"2009","unstructured":"Tehrani F, Dhesi P, Daneshvar D, Phan A, Rafique A, Siegel RJ, Cercek B. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Cardiovasc Drugs Ther. 2009, 23:511-8. 10.1007\/s10557-009-6203-6","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg K","year":"2013","unstructured":"Swedberg K, Young JB, Anand IS, et al.. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013, 368:1210-9. 10.1056\/NEJMoa1214865","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23598","article-title":"Evaluation and management of anemia in the elderly","volume":"89","author":"Goodnough LT","year":"2014","unstructured":"Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol. 2014, 89:88-96. 10.1002\/ajh.23598","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.512988","article-title":"Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT","volume":"112","author":"Anand IS","year":"2005","unstructured":"Anand IS, Kuskowski MA, Rector TS, et al.. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005, 112:1121-7. 10.1161\/CIRCULATIONAHA.104.512988","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi388","article-title":"Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure","volume":"26","author":"Opasich C","year":"2005","unstructured":"Opasich C, Cazzola M, Scelsi L, et al.. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005, 26:2232-7. 10.1093\/eurheartj\/ehi388","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.9.1425","article-title":"Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure","volume":"15","author":"McMahon LP","year":"2000","unstructured":"McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant. 2000, 15:1425-30. 10.1093\/ndt\/15.9.1425","journal-title":"Nephrol Dial Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer P","year":"2005","unstructured":"van der Meer P, Lipsic E, Westenbrink BD, et al.. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005, 112:1743-7. 10.1161\/CIRCULATIONAHA.105.549121","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a059508","article-title":"Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones","volume":"10","author":"Anand IS","year":"1989","unstructured":"Anand IS, Veall N, Kalra GS, et al.. Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones. Eur Heart J. 1989, 10:445-50. 10.1093\/oxfordjournals.eurheartj.a059508","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2008.08.006","article-title":"Iron metabolism in the anemia of chronic disease","volume":"1790","author":"Weiss G","year":"2009","unstructured":"Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009, 1790:682-93. 10.1016\/j.bbagen.2008.08.006","journal-title":"Biochim Biophys Acta"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal S","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, et al.. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017, 377:111-21. 10.1056\/NEJMoa1701719","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540360041028","article-title":"Prevalence of iron deficiency in the United States","volume":"277","author":"Looker AC","year":"1997","unstructured":"Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. JAMA. 1997, 277:973-6. 10.1001\/jama.1997.03540360041028","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko DO","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, et al.. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008, 51:103-12. 10.1016\/j.jacc.2007.09.036","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.015","article-title":"Intravenous iron alone for the treatment of anemia in patients with chronic heart failure","volume":"48","author":"Bolger AP","year":"2006","unstructured":"Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006, 48:1225-7. 10.1016\/j.jacc.2006.07.015","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(00)00613-6","article-title":"The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations","volume":"35","author":"Silverberg DS","year":"2000","unstructured":"Silverberg DS, Wexler D, Blum M, et al.. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000, 35:1737-44. 10.1016\/s0735-1097(00)00613-6","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski P","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J. 2015, 36:657-68. 10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000358377","article-title":"Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients","volume":"128","author":"Rangel I","year":"2014","unstructured":"Rangel I, Gon\u00e7alves A, de Sousa C, et al.. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology. 2014, 128:320-6. 10.1159\/000358377","journal-title":"Cardiology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency","volume":"50","author":"Toblli JE","year":"2007","unstructured":"Toblli JE, Lombra\u00f1a A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007, 50:1657-65. 10.1016\/j.jacc.2007.07.029","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2011.77","article-title":"Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches","volume":"8","author":"van Veldhuisen DJ","year":"2011","unstructured":"van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011, 8:485-93. 10.1038\/nrcardio.2011.77","journal-title":"Nat Rev Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker SD","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009, 361:2436-48. 10.1056\/NEJMoa0908355","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/185920-intravenous-iron-technique-evaluation-in-chronic-heart-failure-with-iron-deficiency-anemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:53Z","timestamp":1707509273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/185920-intravenous-iron-technique-evaluation-in-chronic-heart-failure-with-iron-deficiency-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.47778","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}